ArticleThe Journal of pediatrics2008
Growth hormone treatment for growth failure in pediatric patients with Crohn's disease.
Article in The Journal of pediatrics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Hormonal therapy for impaired growth due to pediatric-onset inflammatory bowel disease: a systematic review and meta-analysis with trial sequential analysis.Journal of pediatric endocrinology & metabolism : JPEM · 2025Pooled it
- A randomized controlled trial of growth hormone in active pediatric Crohn disease.Journal of pediatric gastroenterology and nutrition · 2010Trial
- [Prospects and mechanistic insights into the use of recombinant human growth hormone in the treatment of pediatric inflammatory bowel disease].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Review
- Understanding Inflammatory Bowel Disease in Women From Puberty to Menopause.Gastroenterology & hepatology · 2025Article
- Characterization of Growth Hormone Resistance in Experimental and Ulcerative Colitis.International journal of molecular sciences · 2017Article
- Growth Hormone Resistance-Special Focus on Inflammatory Bowel Disease.International journal of molecular sciences · 2017Review
- Assessing the feasibility of injectable growth-promoting therapy in Crohn's disease.Pilot and feasibility studies · 2016Article
- Endocrine therapy for growth retardation in paediatric inflammatory bowel disease.Paediatric drugs · 2014Review
- categoryCompare, an analytical tool based on feature annotations.Frontiers in genetics · 2014Article
- Delays in puberty, growth, and accrual of bone mineral density in pediatric Crohn's disease: despite temporal changes in disease severity, the need for monitoring remains.The Journal of pediatrics · 2013Review
- Article
- Endocrine and metabolic manifestations in inflammatory bowel disease.Annals of gastroenterology · 2012Review
- Use of ghrelin as a treatment for inflammatory bowel disease: mechanistic considerations.International journal of peptides · 2011Article
- Association of linear growth impairment in pediatric Crohn's disease and a known height locus: a pilot study.Annals of human genetics · 2010Article
- Nutritional status and nutritional therapy in inflammatory bowel diseases.World journal of gastroenterology · 2009Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
Abstract
objectiveTo investigate the effect of human growth hormone (GH) injections on growth velocity in growth-impaired children with Crohn's disease (CD). STUDY
designTen children and adolescents (mean age, 12.6 +/- 4.5 years; 6 males) with CD and poor height growth were treated with open-label recombinant GH, 0.043 mg/kg/day administered via subcutaneous injection, for 1 year. Patients were retrospectively matched with untreated patients (3 comparisons per case) by race, age, sex, and baseline height. Primary endpoint was height velocity; secondary endpoints were disease activity, body composition, and bone density determined by dual-energy x-ray absorptiometry scan.
resultsMean height velocity increased by 5.33 +/- 3.40 (mean +/- standard deviation) cm/year in the GH-treated patients during the year of GH treatment, compared with 0.96 +/- 3.52 cm/year in the comparison group (P = .03). Height z-score increased by 0.76 +/- 0.38 in the treated group, compared with 0.16 +/- 0.40 in the comparison group (P < .01), and weight z-score increased by 0.81 +/- 0.89 in the treated group, compared with 0.00 +/- 0.57 in the comparison group (P < .01). Bone density revealed an increase of 0.31 +/- 0.33 in the lumbar spine z-score (P = .03 vs baseline).
conclusionsGH treatment increases height velocity and may enhance bone mineralization in children with CD. A randomized controlled trial in a large cohort of children is needed to evaluate the ultimate impact of GH treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.